0 XP   0   0   0

Marvel Biosciences Corp
Buy, Hold or Sell?

Should you buy, hold or sell Marvel Biosciences Corp?

I guess you are interested in Marvel Biosciences Corp. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

Let's analyse Marvel Biosciences Corp

Let's start. I'm going to help you getting a better view of Marvel Biosciences Corp. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

  1. Company's Financial Health
    A deep dive into the books. How are the numbers doing? Is Marvel Biosciences Corp even making a profit? Is the company skyrocketing? Or is it sinking like the Titanic. The trend is your friend.
  2. Market Valuation
    Finally, you now have an insight of how Marvel Biosciences Corp is doing in the market. If the company is worth buying. The latest step is to find out how other investors value Marvel Biosciences Corp. The closing price on 2023-02-03 was C$0.1 per share. Is the company over- or underpriced?
  3. Key Performance Indicators
    A total overlook on how the company is doing. Based on the (trends in) the key performance indicators.
Marvel Biosciences Corp Daily Candlestick Chart
Marvel Biosciences Corp Daily Candlestick Chart
Summary









1. Valuation of Marvel Biosciences Corp




Current price per share

C$0.10

2. Growth of Marvel Biosciences Corp




Is Marvel Biosciences Corp growing?

Current yearPrevious yearGrowGrow %
How rich?$169.8k$1.5m-$1.2m-431.0%

How much money is Marvel Biosciences Corp making?

Current yearPrevious yearGrowGrow %
Making money-$436k-$968.1k$532k122.0%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Marvel Biosciences Corp




Comparing to competitors in the Biotechnology industry




  Industry Rankings (Biotechnology)  


Richest
#1083 / 1232

Most Revenue
#879 / 1232

Most Profit
#233 / 1232

Most Efficient
#280 / 1232


Summary

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is just able to pay all its debts with equity.

1.1. Profitability of Marvel Biosciences Corp.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Marvel Biosciences Corp earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Marvel Biosciences Corp to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Marvel Biosciences Corp:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--223.6%+223.6%
TTM--281.7%+281.7%
YOY--344.8%+344.8%
5Y--450.1%+450.1%
10Y--541.0%+541.0%
1.1.2. Return on Assets

Shows how efficient Marvel Biosciences Corp is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Marvel Biosciences Corp to the Biotechnology industry mean.
  • -35.3% Return on Assets means that Marvel Biosciences Corp generated $-0.35 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Marvel Biosciences Corp:

  • The MRQ is -35.3%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -67.5%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-35.3%TTM-67.5%+32.2%
TTM-67.5%YOY-54.2%-13.4%
TTM-67.5%5Y-63.1%-4.5%
5Y-63.1%10Y-63.1%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-35.3%-9.9%-25.4%
TTM-67.5%-8.9%-58.6%
YOY-54.2%-9.3%-44.9%
5Y-63.1%-11.7%-51.4%
10Y-63.1%-12.7%-50.4%
1.1.3. Return on Equity

Shows how efficient Marvel Biosciences Corp is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Marvel Biosciences Corp to the Biotechnology industry mean.
  • -130.0% Return on Equity means Marvel Biosciences Corp generated $-1.30 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Marvel Biosciences Corp:

  • The MRQ is -130.0%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -167.0%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-130.0%TTM-167.0%+36.9%
TTM-167.0%YOY-58.1%-108.8%
TTM-167.0%5Y-130.7%-36.3%
5Y-130.7%10Y-130.7%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-130.0%-12.0%-118.0%
TTM-167.0%-11.5%-155.5%
YOY-58.1%-10.8%-47.3%
5Y-130.7%-14.2%-116.5%
10Y-130.7%-15.2%-115.5%

1.2. Operating Efficiency of Marvel Biosciences Corp.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Marvel Biosciences Corp is operating .

  • Measures how much profit Marvel Biosciences Corp makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Marvel Biosciences Corp to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Marvel Biosciences Corp:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--207.3%+207.3%
TTM--271.0%+271.0%
YOY--325.9%+325.9%
5Y--454.0%+454.0%
10Y--537.1%+537.1%
1.2.2. Operating Ratio

Measures how efficient Marvel Biosciences Corp is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Marvel Biosciences Corp:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.871-2.871
TTM-3.504-3.504
YOY-3.604-3.604
5Y-5.132-5.132
10Y-6.371-6.371

1.3. Liquidity of Marvel Biosciences Corp.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Marvel Biosciences Corp is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 1.37 means the company has $1.37 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Marvel Biosciences Corp:

  • The MRQ is 1.373. The company is just able to pay all its short-term debts.
  • The TTM is 2.785. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.373TTM2.785-1.412
TTM2.785YOY14.503-11.719
TTM2.7855Y6.691-3.906
5Y6.69110Y6.6910.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.3735.117-3.744
TTM2.7855.755-2.970
YOY14.5035.854+8.649
5Y6.6916.511+0.180
10Y6.6916.222+0.469
1.3.2. Quick Ratio

Measures if Marvel Biosciences Corp is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Marvel Biosciences Corp to the Biotechnology industry mean.
  • A Quick Ratio of 0.00 means the company can pay off $0.00 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Marvel Biosciences Corp:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM0.113-0.113
TTM0.113YOY0.287-0.174
TTM0.1135Y0.171-0.058
5Y0.17110Y0.1710.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-4.284-4.284
TTM0.1134.664-4.551
YOY0.2874.787-4.500
5Y0.1715.218-5.047
10Y0.1715.182-5.011

1.4. Solvency of Marvel Biosciences Corp.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Marvel Biosciences Corp assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Marvel Biosciences Corp to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.73 means that Marvel Biosciences Corp assets are financed with 72.8% credit (debt) and the remaining percentage (100% - 72.8%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Marvel Biosciences Corp:

  • The MRQ is 0.728. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.534. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.728TTM0.534+0.195
TTM0.534YOY0.094+0.440
TTM0.5345Y0.387+0.147
5Y0.38710Y0.3870.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7280.278+0.450
TTM0.5340.277+0.257
YOY0.0940.306-0.212
5Y0.3870.367+0.020
10Y0.3870.403-0.016
1.4.2. Debt to Equity Ratio

Measures if Marvel Biosciences Corp is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Marvel Biosciences Corp to the Biotechnology industry mean.
  • A Debt to Equity ratio of 268.3% means that company has $2.68 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Marvel Biosciences Corp:

  • The MRQ is 2.683. The company is unable to pay all its debts with equity. -1
  • The TTM is 1.851. The company is just able to pay all its debts with equity.
Trends
Current periodCompared to+/- 
MRQ2.683TTM1.851+0.832
TTM1.851YOY0.106+1.745
TTM1.8515Y1.270+0.582
5Y1.27010Y1.2700.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.6830.315+2.368
TTM1.8510.317+1.534
YOY0.1060.319-0.213
5Y1.2700.403+0.867
10Y1.2700.462+0.808

2. Market Valuation of Marvel Biosciences Corp

2. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Marvel Biosciences Corp generates.

  • Above 15 is considered overpriced but always compare Marvel Biosciences Corp to the Biotechnology industry mean.
  • A PE ratio of -15.45 means the investor is paying $-15.45 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Marvel Biosciences Corp:

  • The EOD is -13.432. Company is losing money. -2
  • The MRQ is -15.447. Company is losing money. -2
  • The TTM is -10.458. Company is losing money. -2
Trends
Current periodCompared to+/- 
EOD-13.432MRQ-15.447+2.015
MRQ-15.447TTM-10.458-4.989
TTM-10.458YOY-12.035+1.577
TTM-10.4585Y-10.983+0.526
5Y-10.98310Y-10.9830.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-13.432-8.986-4.446
MRQ-15.447-9.792-5.655
TTM-10.458-16.243+5.785
YOY-12.035-20.876+8.841
5Y-10.983-16.665+5.682
10Y-10.983-14.732+3.749
2.2. Price Earnings to Growth Ratio

Measures the predicted future growth of Marvel Biosciences Corp.

  • Lower is better.
  • A PEG ratio of 1 means the market price of the stock and the expected future earnings are on par.

Let's take a look of the Price Earnings to Growth Ratio trends of Marvel Biosciences Corp:

  • The MRQ is -10.360. Very Bad. -2
  • The TTM is 10.286. Seems overpriced? -1
Trends
Current periodCompared to+/- 
MRQ-10.360TTM10.286-20.647
TTM10.286YOY-11.105+21.391
TTM10.2865Y6.008+4.278
5Y6.00810Y6.0080.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-10.360-0.032-10.328
TTM10.2860.004+10.282
YOY-11.1050.016-11.121
5Y6.0080.006+6.002
10Y6.0080.003+6.005

2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Marvel Biosciences Corp is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 20.08 means the investor is paying $20.08 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Marvel Biosciences Corp:

  • The EOD is 17.462. Seems overpriced? -1
  • The MRQ is 20.082. Seems overpriced? -1
  • The TTM is 15.219. Seems overpriced? -1
Trends
Current periodCompared to+/- 
EOD17.462MRQ20.082-2.619
MRQ20.082TTM15.219+4.863
TTM15.219YOY4.722+10.497
TTM15.2195Y11.720+3.499
5Y11.72010Y11.7200.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD17.4621.835+15.627
MRQ20.0822.006+18.076
TTM15.2192.774+12.445
YOY4.7223.453+1.269
5Y11.7202.713+9.007
10Y11.7202.402+9.318
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Marvel Biosciences Corp compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.001-0.010+1352%0.023-96%0.001-15%0.001-15%
Book Value Growth--1.1650.647+80%0.783+49%0.675+73%0.675+73%
Book Value Per Share--0.0060.010-42%0.053-89%0.024-76%0.024-76%
Book Value Per Share Growth--1.1650.647+80%0.783+49%0.675+73%0.675+73%
Current Ratio--1.3732.785-51%14.503-91%6.691-79%6.691-79%
Debt To Asset Ratio--0.7280.534+36%0.094+679%0.387+88%0.387+88%
Debt To Equity Ratio--2.6831.851+45%0.106+2424%1.270+111%1.270+111%
Dividend Per Share----0%-0%-0%-0%
Eps---0.007-0.015+98%-0.033+338%-0.021+178%-0.021+178%
Eps Growth--1.4910.886+68%1.756-15%1.060+41%1.060+41%
Free Cash Flow Per Share---0.009-0.014+61%-0.011+19%-0.013+47%-0.013+47%
Free Cash Flow Per Share Growth--1.2050.095+1172%1.514-20%0.379+218%0.379+218%
Free Cash Flow To Equity Per Share---0.001-0.005+247%0.025-106%0.005-128%0.005-128%
Free Cash Flow To Equity Per Share Growth--0.857-1.109+229%0.064+1247%-0.875+202%-0.875+202%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---0.134--------
Intrinsic Value_10Y_min---0.132--------
Intrinsic Value_1Y_max---0.051--------
Intrinsic Value_1Y_min---0.050--------
Intrinsic Value_3Y_max---0.124--------
Intrinsic Value_3Y_min---0.119--------
Intrinsic Value_5Y_max---0.163--------
Intrinsic Value_5Y_min---0.154--------
Net Profit Margin----0%-0%-0%-0%
Operating Margin----0%-0%-0%-0%
Operating Ratio----0%-0%-0%-0%
Pb Ratio17.462-15%20.08215.219+32%4.722+325%11.720+71%11.720+71%
Pe Ratio-13.432+13%-15.447-10.458-32%-12.035-22%-10.983-29%-10.983-29%
Peg Ratio---10.36010.286-201%-11.105+7%6.008-272%6.008-272%
Price Per Share0.100-15%0.1150.130-12%0.245-53%0.168-32%0.168-32%
Price To Total Gains Ratio123.159-15%141.63325.765+450%-7.721+105%14.603+870%14.603+870%
Profit Growth--1.4910.886+68%1.756-15%1.060+41%1.060+41%
Quick Ratio---0.113-100%0.287-100%0.171-100%0.171-100%
Return On Assets---0.353-0.675+91%-0.542+53%-0.631+79%-0.631+79%
Return On Equity---1.300-1.670+28%-0.581-55%-1.307+1%-1.307+1%
Total Gains Per Share--0.001-0.010+1352%0.023-96%0.001-15%0.001-15%
Total Gains Per Share Growth--2.1721.307+66%-0.217+110%1.003+117%1.003+117%
Usd Book Value--169832.681294898.130-42%1565764.878-89%718520.379-76%718520.379-76%
Usd Book Value Change Per Share--0.001-0.008+1352%0.017-96%0.001-15%0.001-15%
Usd Book Value Per Share--0.0040.007-42%0.039-89%0.018-76%0.018-76%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.006-0.011+98%-0.024+338%-0.015+178%-0.015+178%
Usd Free Cash Flow---263073.277-423539.075+61%-312431.428+19%-386503.193+47%-386503.193+47%
Usd Free Cash Flow Per Share---0.007-0.011+61%-0.008+19%-0.010+47%-0.010+47%
Usd Free Cash Flow To Equity Per Share---0.001-0.004+247%0.019-106%0.004-128%0.004-128%
Usd Price Per Share0.075-15%0.0860.097-12%0.183-53%0.125-32%0.125-32%
Usd Profit---220790.462-436083.785+98%-968150.118+338%-613439.229+178%-613439.229+178%
Usd Revenue----0%-0%-0%-0%
Usd Total Gains Per Share--0.001-0.008+1352%0.017-96%0.001-15%0.001-15%
 EOD+2 -3MRQTTM+25 -9YOY+14 -205Y+19 -1510Y+19 -15

3.2. Fundamental Score

Let's check the fundamental score of Marvel Biosciences Corp based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-13.432
Price to Book Ratio (EOD)Between0-117.462
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.000
Current Ratio (MRQ)Greater than11.373
Debt to Asset Ratio (MRQ)Less than10.728
Debt to Equity Ratio (MRQ)Less than12.683
Return on Equity (MRQ)Greater than0.15-1.300
Return on Assets (MRQ)Greater than0.05-0.353
Total2/10 (20.0%)

3.3. Technical Score

Let's check the technical score of Marvel Biosciences Corp based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5039.032
Ma 20Greater thanMa 500.113
Ma 50Greater thanMa 1000.128
Ma 100Greater thanMa 2000.118
OpenGreater thanClose0.105
Total3/5 (60.0%)



Latest Balance Sheet

Balance Sheet of 2022-10-31. Currency in CAD. All numbers in thousands.

Summary
Total Assets839
Total Liabilities611
Total Stockholder Equity228
 As reported
Total Liabilities 611
Total Stockholder Equity+ 228
Total Assets = 839

Assets

Total Assets839
Total Current Assets839
Long-term Assets839
Total Current Assets
Cash And Cash Equivalents 536
Total Current Assets  (as reported)839
Total Current Assets  (calculated)536
+/- 303
Long-term Assets
Long-term Assets  (as reported)0
Long-term Assets  (calculated)0
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities611
Long-term Liabilities0
Total Stockholder Equity228
Total Current Liabilities
Accounts payable 205
Total Current Liabilities  (as reported)611
Total Current Liabilities  (calculated)205
+/- 406
Long-term Liabilities
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/-0
Total Stockholder Equity
Total Stockholder Equity (as reported)228
Total Stockholder Equity (calculated)0
+/- 228
Other
Capital Stock7,127
Common Stock Shares Outstanding 39,786
Net Invested Capital 228
Net Working Capital 228



Balance Sheet

Currency in CAD. All numbers in thousands.

 Trend2022-10-312022-07-312022-04-302022-01-312021-10-312021-07-312021-04-302021-01-312020-10-312019-10-31
> Total Assets 
0
0
0
0
2,468
2,150
921
714
914
839
8399147149212,1502,4680000
   > Total Current Assets 
0
395
439
209
2,468
2,150
921
714
914
839
8399147149212,1502,4682094393950
       Cash And Cash Equivalents 
0
0
0
0
2,393
2,119
859
643
593
536
5365936438592,1192,3930000
       Net Receivables 
0
48
64
47
59
15
33
48
56
0
056483315594764480
       Other Current Assets 
0
35
35
35
16
16
29
23
252
0
0252232916163535350
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0000000000
       Property Plant Equipment 
0
0
0
0
0
0
0
0
0
0
0000000000
> Total Liabilities 
0
0
0
0
112
304
145
331
718
611
6117183311453041120000
   > Total Current Liabilities 
0
218
217
334
112
304
145
331
718
611
6117183311453041123342172180
       Accounts payable 
0
107
132
181
2
31
5
195
262
205
20526219553121811321070
       Other Current Liabilities 
0
9
0
0
0
0
4
16
26
0
026164000090
   > Long-term Liabilities 0000000000
> Total Stockholder Equity
0
0
0
0
2,356
1,845
776
383
196
228
2281963837761,8452,3560000
   Common Stock
0
1,311
1,558
1,892
6,460
6,460
6,460
6,460
6,861
0
06,8616,4606,4606,4606,4601,8921,5581,3110
   Retained Earnings Total Equity0000000000
   Accumulated Other Comprehensive Income 0000000000
   Capital Surplus 0000000000
   Treasury Stock0000000000
   Other Stockholders Equity 0-3000000000



Balance Sheet

Currency in CAD. All numbers in thousands.




Cash Flow

Currency in CAD. All numbers in thousands.




Income Statement

Currency in CAD. All numbers in thousands.


Latest Income Statement (annual, 2022-07-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-1,377
Gross Profit-1,377-1,377
 
Operating Income (+$)
Gross Profit-1,377
Operating Expense-2,548
Operating Income-2,548-3,925
 
Operating Expense (+$)
Research Development-
Selling General Administrative1,171
Selling And Marketing Expenses-
Operating Expense2,5481,171
 
Net Interest Income (+$)
Interest Income0
Interest Expense--
Net Interest Income-20
 
Pretax Income (+$)
Operating Income-2,548
Net Interest Income-2
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-2,554-2,544
EBIT - interestExpense = -2,506
-2,554
-2,554
Interest Expense-
Earnings Before Interest and Taxes (ebit)-2,506-2,554
Earnings Before Interest and Taxes (ebitda)-2,548
 
After tax Income (+$)
Income Before Tax-2,554
Tax Provision--
Net Income From Continuing Ops-2,554-2,554
Net Income-2,554
Net Income Applicable To Common Shares-2,554
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-42
 

Comments

Join the conversation.

Leave a comment

Stay informed with my latest content.

Subscribe to my newsletter and receive an email as soon as I add content to PenkeTrading.com.


By clicking Register, you agree to the General Terms and Conditions.
Penke's Market Notifications